Stockscreener 앱 받기
1.27
0.00%
0.00
시간 외 거래:
1.27
전일 마감가:
$1.27
열려 있는:
$1.26
하루 거래량:
10,529
Relative Volume:
0.84
시가총액:
$69.16M
수익:
-
순이익/손실:
$-9.51M
주가수익비율:
-6.6842
EPS:
-0.19
순현금흐름:
$-10.96M
1주 성능:
-5.22%
1개월 성능:
-9.93%
6개월 성능:
-40.38%
1년 성능:
-9.29%
1일 변동 폭
$1.26
$1.32
1주일 범위
$1.26
$1.33
52주 변동 폭
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
명칭
Medicinova Inc
전화
858-373-1500
주소
4275 EXECUTIVE SQUARE, LA JOLLA, CA
MNOV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.27 | 69.16M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-10 | 개시 | Maxim Group | Buy |
| 2019-03-25 | 재개 | B. Riley FBR | Buy |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 개시 | Credit Suisse | Outperform |
| 2013-01-04 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-24 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2011-10-18 | 재확인 | MLV Capital | Buy |
| 2011-06-22 | 개시 | Global Hunter Securities | Buy |
| 2010-05-12 | 개시 | Wedbush | Outperform |
| 2008-11-12 | 재확인 | Ladenburg Thalmann | Buy |
| 2008-05-15 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 개시 | Punk, Ziegel & Co | Buy |
모두보기
Medicinova Inc 주식(MNOV)의 최신 뉴스
Medicinova Announces Results of Annual Stockholders Meeting - TipRanks
What is B. Riley’s Forecast for MediciNova Q2 Earnings? - Defense World
MediciNova (NASDAQ:MNOV) Price Target Cut to $5.00 by Analysts at B. Riley - Defense World
MediciNova (MNOV) Stock: Analyst Lowers Price Target, Maintains Buy Rating | MNOV Stock News - GuruFocus
B. Riley Lowers Price Target on MediciNova to $5 From $6, Keeps Buy Rating - MarketScreener
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Bank of America Corp DE - Defense World
Jane Street Group LLC Acquires 9,121 Shares of MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Bank of America Corp DE Has $696,000 Holdings in Canaan Inc. (NASDAQ:CAN) - Defense World
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Diabetes Market to Reach New Heights in Growth by 2032, - openPR.com
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova: Q1 Earnings Snapshot - San Antonio Express-News
Barclays PLC Purchases 12,800 Shares of MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Geode Capital Management LLC Raises Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - The Manila Times
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - GlobeNewswire
MediciNova Secures Spotlight at Exclusive Healthcare Conference: CEO to Reveal Latest Pipeline Progress - Stock Titan
Meta CEO Mark Zuckerberg takes the stand in historic antitrust trial - The Globe and Mail
MediciNova’s (MNOV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Texas Instruments (TXN) Stock Trades Down, Here Is Why - The Globe and Mail
First Patient Enrolled in NIH-Funded Expanded Access - GlobeNewswire
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - TradingView
This Stock Has More Than Doubled Already in 2025. Is It a Buy? - The Globe and Mail
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
MEDICINOVA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Why AppLovin (APP) Shares Are Trading Lower Today - The Globe and Mail
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
Carter's (CRI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid CSX and 1 Stock to Buy Instead - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Top Companies - openPR
Y Intercept Hong Kong Ltd Makes New $78,000 Investment in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Should You Forget Tesla and Buy 2 Artificial Intelligence (AI) Stocks Right Now? - The Globe and Mail
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
MKS Instruments to Participate in Cantor Fitzgerald Global Technology Conference - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - The AM Reporter
MediciNova (NASDAQ:MNOV) Issues Earnings Results - MarketBeat
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
Medicinova Inc (MNOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):